Ventyx Biosciences, Inc. Logo

Ventyx Biosciences, Inc.

Clinical-stage biopharma developing oral therapies for autoimmune, inflammatory & neuro diseases.

VTYX | US

Overview

Corporate Details

ISIN(s):
US92332V1070
LEI:
Country:
United States of America
Address:
12790 EL CAMINO REAL, SUITE 200, 92130 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. Leveraging expertise in medicinal chemistry, structural biology, and immunology, the company discovers and advances differentiated small molecule therapeutics for conditions with high unmet medical need. Its pipeline includes NLRP3 inhibitors VTX2735 (Phase 2 for recurrent pericarditis) and VTX3232 (Phase 2 for neurodegenerative and cardiometabolic diseases). The inflammatory bowel disease portfolio features S1P1R modulator tamuzimod and TYK2 inhibitor VTX958, both of which have completed Phase 2 clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ventyx Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ventyx Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ventyx Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark
GMAB
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea
225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea
314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea
228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland
GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea
066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America
GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway
GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America
GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America
GHRS

Talk to a Data Expert

Have a question? We'll get back to you promptly.